Figure 4. (A) Sino nasal outcome test (SNOT-22) symptoms survey is significantly reduced after 20 weeks treatment with benralizumab (P=0.001) and in the placebo group (P=0.024). (B) Nasal blockage score (NBS) component of the SNOT-22 questionnaire is significantly lower in the benralizumab treatment group (P=0.038) but not placebo (P=0.399).